Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835333 | 0.97 | EGFR (0.70) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL4865656 | 0.91 | EGFR (0.62) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL21835274 | 0.88 | EGFR (0.73) | EGFRERBB2KCNH2LCK | |
| SCHEMBL21835414 | 0.88 | EGFR (0.62) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL21835412 | 0.88 | EGFR (0.69) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL23406696 | 0.86 | EGFR (0.70) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL21835342 | 0.86 | EGFR (0.70) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL13195990 | 0.86 | EGFR (0.73) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL17498553 | 0.86 | EGFR (0.73) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL23406726 | 0.86 | EGFR (0.71) | EGFRERBB2KCNH2LCKEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-113382986-A | Tyrosine kinase inhibitor compositions, methods of making and methods of using the same | 黑钻治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885KCNH2 4742/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885KCNH2 4742/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885KCNH2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.